Search

Your search keyword '"Flack, Robert"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Flack, Robert" Remove constraint Author: "Flack, Robert"
40 results on '"Flack, Robert"'

Search Results

1. Cold Atoms in Space: Community Workshop Summary and Proposed Road-Map

2. AEDGE: Atomic Experiment for Dark Matter and Gravity Exploration in Space

3. Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancers

5. AEDGE: Atomic Experiment for Dark Matter and Gravity Exploration in Space

6. Supplementary Methods from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

7. Data from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

8. Supplementary Figure S4 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

9. Supplementary Table S3 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

10. Supplementary tables and figures from Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

11. Cold atoms in space: community workshop summary and proposed road-map

12. Evolution of Architectural Floor Plans

13. Cold atoms in space: community workshop summary and proposed road-map

14. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

16. AEDGE:Atomic Experiment for Dark Matter and Gravity Exploration in Space

18. ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

20. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

21. Abstract B43: The CDK4 and 6 inhibitor abemaciclib induces both epigenetic and immunogenic responses in preclinical models of Ewing’s sarcoma

25. Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

26. Abstract 3231: Identifying high quality, potent and selective pyrimidinylthienopyrrolone inhibitors of ERK1/2 kinase: LY3214996

27. Abstract 317: Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC)

28. Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations

29. Abstract 930: Combined inhibition of pan-RAF and VEGFR-2 mediates antitumor activity in KRAS mutant non-small cell lung cancer (NSCLC) through enhanced inhibition of tumor angiogenesis and growth

30. Window Shopping

31. Measurement of the double-beta decay half-life on Nd-150 and search for neutrinoless decay modes with the NEMO-3 detector

33. Measurement of the background in the NEMO 3 double beta decay experiment

34. Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.

37. Robert Flack : This is True to Me

40. A Sturdy Stance.

Catalog

Books, media, physical & digital resources